Skip to content

Turmeric Oral Rinse in Oral Mucositis

An Open Label, Clinical Study to Evaluate the Efficacy and Safety of Turmeric Oral Rinse in Oral Mucositis During Cancer Chemotherapy and Radiotherapy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013936
Enrollment
40
Registered
2018-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Subjects with head and neck cancer scheduled to receive chemotherapy or radiotherapy as standard care and with history or prone to develop oral mucositis during cancer chemotherapy or radiotherapy

Interventions

Intervention1: Turmeric Oral Rinse: subjects will be advised to use 10 ml of oral rinse for 1 minute 4 times daily for a period of 6 weeks starting from day 1 of standard anticancer care. Control Inte

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Subjects with confirmed histopathologically with head and neck cancer (according to TNM classification) preferably oropharyngeal scheduled to receive chemotherapy or radiotherapy as a standard care. 2 Subjects with history or prone to develop oral mucositis during cancer chemotherapy or radiotherapy. 3 Subjects aged >18 years of either the sex. 4 Subjects willing to give a written informed consent and follow the schedule of the study as per the protocol.

Exclusion criteria

Exclusion criteria: 1 Has participated in a similar clinical investigation in the past four weeks. 2 Severe uncontrolled systemic disorders, diabetes, Hypertension, or genetic and endocrinal disorders. 3 Has used a similar product in the past four weeks. 4 Subjects who refused to sign informed consent. 5 Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Mucositis Assessment: Condition of the patientâ??s mouth is assessed at weekly intervals, as per the World Health Organisation grading of mucositisTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week

Secondary

MeasureTime frame
Burning sensationTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week;Difficulty in chewingTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week;Difficulty in drinkingTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week;Difficulty in opening the mouthTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week;Location of ulcersTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week;Number of ulcersTimepoint: At entry, end of 1st week, end of 2nd week, end of 3rd week, end of 4th week, end of 5th week and end of 6th week

Countries

India

Contacts

Public ContactDr Padmanabha

M.S.Ramaiah Hospital

kirthi.koushik@gmail.com09901845412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026